| __timestamp | Novartis AG | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 2917513 |
| Thursday, January 1, 2015 | 14247000000 | 7878291 |
| Friday, January 1, 2016 | 14192000000 | 8366794 |
| Sunday, January 1, 2017 | 14997000000 | 6610381 |
| Monday, January 1, 2018 | 16471000000 | 6556000 |
| Tuesday, January 1, 2019 | 14369000000 | 6930000 |
| Wednesday, January 1, 2020 | 14197000000 | 8758000 |
| Friday, January 1, 2021 | 14886000000 | 10806000 |
| Saturday, January 1, 2022 | 14253000000 | 9844000 |
| Sunday, January 1, 2023 | 12489000000 | 13481000 |
| Monday, January 1, 2024 | 12566000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 offers a fascinating glimpse into the financial strategies of Novartis AG and Soleno Therapeutics, Inc. Over this period, Novartis AG consistently maintained high SG&A expenses, peaking in 2018 with a 13% increase from 2014. However, a notable decline of 24% was observed by 2023, reflecting strategic cost-cutting measures.
Conversely, Soleno Therapeutics, Inc. exhibited a more volatile pattern, with expenses surging by 362% from 2014 to 2023. This dramatic rise underscores the company's aggressive expansion and investment in growth initiatives. The contrasting trends between these two companies highlight the diverse approaches to managing operational costs in the pharmaceutical sector, offering valuable insights for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.